NIKKEI 225
30,634.89 -603.05 (-1.93%) HANG SENG
17,214.01 -117.21 (-0.68%) CRUDE OIL
89.19 -0.04 (-0.04%) GOLD FUTURES
1,836.30 -5.20 (-0.28%) DOW
33,002.38 -430.97 (-1.29%) Bitcoin GBP
22,739.84 -104.37 (-0.46%)
Chr. Hansen Holding A/S (CHR.CO)
| Previous close | 419.30 |
| Open | 420.10 |
| Bid | 427.90 x 0 |
| Ask | 429.40 x 0 |
| Day's range | 419.90 - 432.00 |
| 52-week range | 360.10 - 604.00 |
| Volume | |
| Avg. volume | 116,975 |
| Market cap | 56.51B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 34.13 |
| EPS (TTM) | 12.58 |
| Earnings date | 12 Oct 2023 |
| Forward dividend & yield | 7.04 (1.68%) |
| Ex-dividend date | 24 Nov 2022 |
| 1y target est | 514.47 |
Globe NewswireMajor shareholder announcements from Burlington Loan Management DAC and Davidson Kempner Capital Management LP
September 27, 2023 – Company announcement no. 8 Please see attachment. Contact information Investor RelationsAnders Mohr Christensen+45 2515 2364dkamc@chr-hansen.com Press RelationsSanne Seyer-Hansen+45 6038 6207dksash@chr-hansen.com About Chr. Hansen Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen, we are strongly positioned to drive positive change through
- Globe Newswire
Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. SEPTEMBER 4, 2023 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies. Re
- Globe Newswire
Chr. Hansen Holding A/S Interim Report Q3 2022/23
July 6, 2023 – Company announcement no. 7 Strong execution by the organization drives solid Q3 results Statement by CEO Mauricio Graber: “The solid results for Q3 prove the strength of the Chr. Hansen organization which continues to deliver first-class products and innovative solutions to customers around the world, while the process with Novozymes to complete the proposed merger is progressing. Organic growth came in at 9%, driven mainly by pricing initiatives. EBIT b.s.i. increased by 9% despi
